@article{17592,
  keywords = {Antibodies, Anticardiolipin, Antiphospholipid Syndrome, Beta 2-Glycoprotein I, Enzyme-Linked Immunosorbent Assay, Glycoproteins, Humans, leprosy},
  author = {Hojnik M and Gilburd B and Ziporen L and Blank M and Tomer Y and Scheinberg M A and Tincani A and Rozman B and Shoenfeld Y},
  title = {Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy.},
  abstract = {<p>We studied the effect of beta 2-GPI on binding of antibodies in sera from patients with leprosy and patients with the antiphospholipid syndrome (APS) to CL in enzyme-linked immunosorbent assays (ELISAs). Increased levels of IgG aCL were detected in 59 of 61 leprosy patients' sera by the standard aCL-ELISA in the presence of bovine beta 2-GPI and in 60 of the 61 leprosy patients' sera by the modified aCL-ELISA without beta 2-GPI. When tested by both aCL-ELISAs on the same plate, 10/31 leprosy sera and 9/10 APS sera bound better in the standard aCL-ELISA, 16/31 leprosy sera bound better in the modified aCL-ELISA and in five leprosy and one APS sera the difference was not significant. A dose-dependent enhancing effect of beta 2-GPI on the leprosy and APS sera binding to CL was confirmed using purified human beta 2-GPI. Enhanced binding was seen if beta 2-GPI was added either before or together with the test serum. In 11/61 leprosy sera increased levels of IgG antibodies against beta 2-GPI were found by ELISA. Leprosy anti-beta 2-GPI antibodies appear to be a separate antibody population recognizing only beta 2-GPI adsorbed on the ELISA plate. These results demonstrate heterogeneity of leprosy aCL with respect to their beta 2-GPI requirement for binding to CL.</p>},
  year = {1994},
  journal = {Lupus},
  volume = {3},
  pages = {515-21},
  month = {1994 Dec},
  issn = {0961-2033},
  doi = {10.1177/096120339400300615},
  language = {eng},
}